A B S T R A C T Hyperaminoacidemia is a powerful stimulus of pancreatic glucagon secretion. These studies were designed to elucidate the role of aminogenic hyperglucagonemia in glucoregulation. Conscious dogs with previously implanted indwelling venous catheters were employed. The results support the view that a role of glucagon is to limit blood glucose decline during hyperaminoacidemia.
A B S T R A C T Hyperaminoacidemia is a powerful stimulus of pancreatic glucagon secretion. These studies were designed to elucidate the role of aminogenic hyperglucagonemia in glucoregulation. Conscious dogs with previously implanted indwelling venous catheters were employed. The results support the view that a role of glucagon is to limit blood glucose decline during hyperaminoacidemia.
First, a significant negative correlation between the area of glucagon increment during the 1st 20 min of a 10 amino acid infusion and the maximum fall in glucose concentration was observed. Second, when endogenous glucagon secretion was suppressed by means of a continuous glucose infusion, hyperaminoacidemia induced a maximal glucose decline which averaged 35 mg/100 ml, differing significantly from mean maximal fall of 3 mg/100 ml, which normally occurs in the presence of endogenous hyperglucagonemia. Third, when, during hyperglycemic suppression of endogenous glucagon secretion, 50 mug of exogenous glucagon/min was infused via the mesenteric vein with the amino acids, the fall in glucose was reduced to an average of 5 mg/100 ml. Similarly when pancreozymin, administered during the combined infusion of glucose and amino acids, overcame glucose suppression of endogenous glucagon secretion, plasma glucose did not fall.
Similar results were obtained when aminogenic hyperglucagonemia was prevented by other means. Hyperlipacidemia, induced by infusing a triglyceride emulsion and giving heparin injections, also suppressed aminogenic hyperglucagonemia in two of four experiments; in these two dogs glucose fell 15 and 11 mg/100 ml. In a final group of experiments, the canine pancreas was resected except for the uncinate process, which is virReceived for publication 8 August 1968 and in revised form 24 October 1968. tually devoid of a-cells. In two dogs, in which this procedure resulted in zero portal venous glucagon levels, the administration of amino acids and/or pancreozymin resulted in a glucose decline of 14 and 16 mg/100 ml, despite the reduced 8-cell population resulting from the subtotal pancreotectomy.
It thus appears that the secretion of pancreatic glu-INTRODUCTION Recent studies indicate that glucagon, the glycogenolytic, gluconeogenic hormone secreted by the pancreas in response to glucose need (1, 2,1), is also stimulated by hyperaminoacidemia (3) (4) (5) . Of the three known stimuli of pancreatic glucagon secretion, hypoglycemia, pancreozymin administration, and hyperaminoacidemia, only the latter would, in the strictest sense, appear to constitute a regularly occurring physiologic event. Therefore, it may well be that an understanding of the function of aminogenic hyperglucagonemia would provide knowledge of glucagon's most important physiologic function.
As has been suggested previously (5) , the purpose of aminogenic hyperglucagonemia may be to prevent a decline in blood glucose concentration secondary to aminogenic insulin secretion during carbohydrate-free protein meals. This point of view is supported by the following observations: first, during hyperaminoacidemia glucagon secretion increases virtually in parallel to insulin secretion, yet, despite the hyperinsulinemia glu-cose concentration declines only slightly (5); and second, infusion of glucose prevents aminogenic hyperglucagonemia, suggesting that it is superfluous when exogenous glucose is available (5) .
The present study was designed to elucidate the role of aminogenic hyperglucagonemia in blood glucose homeostasis by determining the effect of suppression and restoration of hyperglucagonemia upon the plasma glucose response to hyperaminoacidemia.
Inasmuch as a permanent glucagon deficiency state could not be induced pharmacologically by the alphacytotoxic agents cobaltous chloride (6) or neutral red,' other means were used in an attempt to prevent aminogenic hyperglucagonemia. Hyperglycemia (1, 2) and hyperlipacidemia (7) have both been reported to inhibit glucagon secretion and were, therefore, employed to bring about physiologic suppression. The uncinate process of the canine pancreas has been shown by Bencosme and Liepa (8) to be almost devoid of alpha cells and glucagon, and selective resection of all other regions of the pancreas was, therefore, carried out to produce a chronic state of glucagon deficiency.
METHODS

Experimental preparations
Triply catheterized dogs. A triply catheterized dog preparation was employed in most of the experiments to permit sampling from the pancreaticoduodenal vein and the inferior vena cava in fully conscious dogs, and to make possible the infusion of solutions via the mesenteric vein. As has been pointed out previously (5), measurement of glucagon in the pancreatic venous effluent minimizes certain problems of sensitivity and specificity that have plagued attempts to measure glucagon in the peripheral blood.
2 or more days before each experiment, a dog was anesthetized with pentobarbital and the abdomen was opened by midline incision under sterile conditions. A small glass T cannula connected to Teflon tubing was inserted into the superior pancreaticoduodenal vein at a distance of about 3 cm from its junction with the portal vein. The tubing was fixed at the duodenum with a suture. A second Teflon catheter was inserted through the left jugular vein and was fixed in place with its opening reposing in the inferior vena cava between the heart and the hepatic vein. A third catheter, this one of polyethylene, was threaded through a small mesenteric venous radicle into a major mesenteric vein. All catheters were exteriorized, sutured in place, and heavily bandaged with tape. The pancreaticoduodenal vein catheter was perfused continuously until the time of the experiment with diluted heparin-saline solution so as to deliver 100 units of heparin in a volume of 20 ml/hr.
After surgery each animal received an intramuscular injection of 600,000 U of penicillin daily. Dogs were fed on a Purina Chow diet. Recovery from the surgical procedure was uneventful in the majority of dogs. Only dogs that appeared to be in good health were employed for experiments. The appearance of either diarrhea, loss of appetite, weight loss in excess of 1.5 kg, a white blood count above 30,000 (normal ' (14) , and glucagon by the previously described radioimmunoassay as recently modified (15 
RESULTS
Correlation between glucagon rise and decline in glucose during hyperaminoacidemia. It was recently reported that during hyperaminoacidemia in dogs mean concentration of pancreaticoduodenal vein insulin rises 375 uU/ml, the mean pancreaticoduodenal vein glucagon rises 1.6 mjug/ml, and the mean inferior vena caval plasma glucose declines only 3 mg/100 ml (5) . If the hyperglucagonemia is responsible for restricting the magnitude of the fall in glucose concentration, a negative correlation between the increase in glucagon secretion and the decrease in plasma glucose might well exist. To determine this, the previously published data were analyzed. As shown in Fig. 1 , a statistically significant negative correlation (r = -0.588; P <0.025) was observed between maximal glucose fall during the hour after the start of the infusion and the area of glucagon increment during the 1st 20 min.
Variation in the insulin response to hyperaminoacidemia could also account for variations in glucose change. The relationship between the area of insulin increment of the 1st 20 min and maximal fall in glucose within 60 min of the start of the infusion was, therefore, examined. No statistically significant relationship between insulin increment and glucose decline (r = 0.106; P > 0.5) was observed (Fig. 2) .
These findings are compatible with the possibility that glucagon secretion limited the fall in plasma glucose concentration.
Effect of hyperglycemic suppression of aminogenic hyperglucagonemia upon the glucose response to hyperaminoacidemia. If, as the above correlation suggests, increased glucagon secretion was responsible for restricting the magnitude of the decline of glucose during hyperaminoacidemia, then prevention of hyperglucagonemia would result in a larger decline in glucose concentration. Because of earlier studies indicating that hyperglycemia prevents aminogenic hyperglucagonemia (5), a 15% glucose solution was infused at a rate of 200 or 300 mg/min to each of a group of 10 dogs in order to maintain the plasma glucose concentration above 142 mg/100 ml, a level found to inhibit glucagon secretion in most dogs. 60 Fig. 4 . Glucose concentration declined an average of only 5 mg during the 1st 30 min of the glucagon infusion even though pancreaticoduodenal vein insulin rose more than 600 MAU/ml to a maximal mean level of 1253 ,uU/ml.
In four of the six experiments, the glucagon infusion was discontinued after 30 min, after which the glucose level fell an average of 39 mg/100 ml below the zero time level. In two of the dogs (Nos. 384 and 385) the glucagon infusion was continued for a full 60 min, and in the final 30 min the glucose concentration declined to 35 and 48 mg/100 ml below the initial value.7 The 'After the glucagon infusion was stopped in dog Nos. 384 and 385, a further decline in glucose concentration of 11 and 12 mg/100 ml, respectively, was observed. striking decline in glucose in the last 30 min may be related to the enormous rise in insulin unaccompanied by an adequate rise in glucagon. In Table IV the maximal blood glucose decline during the 1st 30 min of amino acid infusion in the six hyperglycemic-hyperaminoacidemic dogs given exogenous glucagon is compared with that of the 10 hyperglycemichyperaminoacidemic dogs of Table II, in which no glucagon was administered. The difference is barely significant (P < 0.05), and suggests that exogenous glucagon may have restricted the aminogenic decline in plasma glucose for 30 min. However, a comparison of the mean insulin levels of the glucagon-treated group (Fig. 4) with that of the untreated "control" group ( Fig. 3 ) reveals it to be higher in the latter, and this, data are not included in Table III , but have been incorporated in Fig. 4 by omitting from these two experiments (dog Nos. 384 and 385) the data of the last 30 min of glucagon infusion and substituting data obtained after stopping the glucagon infusion, thus making the entire group more homogeneous. rather than glucagon lack, could be interpreted as being the cause of the greater decline in plasma glucose. Yet the absolute insulin level reflects the response to the sum of the aminogenic and glycemogenic stimuli, whereas the increment of insulin concentration above the level at "zero time" represents only the amino acid-induced component of the insulin response, and it is this which is most germane to the amino acid-induced glucose response. The mean insulin increment during 30 min of amino acid infusion was calculated for each glucagontreated dog of Table III and each untreated "control"  dog of Table II, and the values recorded in Table IV . The average mean increment of the glucagon-treated group was 456 uU/ml (SEM +109), while in the untreated "control" group it was 488 MU/ml (SEM +99). This lack of a statistically significant difference tends to point away from insulin response as the primary cause of the difference in the glucose response of the groups.
Effect of restoring aminogenic hyperglucagonemia by overcoming suppression of endogenous glucagon secretion. Pancreozymin has recently been demonstrated to be a potent stimulus of both insulin (17, 18) and glucagon secretion (18) and it seemed possible that it might overcome the suppressive effect of hyperglycemia upon glucagon secretion. Pancreozymin was, therefore, infused at a rate of 8 U/min for 20 min in a group of four dogs during hyperglycemic suppression of aminogenic hyperglucagonemia. In two of the experiments, one of which is illustrated in Fig. 5 A, such a "breakthrough" was achieved. In this experiment the infusion of pancreozymin was accompanied by a 2.8 m/g/ml rise in pancreaticoduodenal vein glucagon; despite the associated outpouring of insulin, plasma glucose did not fall, and in fact, rose. In the other experiment glucagon rose 1.9 m/g/ml and glucose fluctuated but never declined more than 8 mg/100 ml. However in two other experiments, one of which is shown in Fig. 5 B, pancreozymin elicited a rise of only 0.7 and 0.8 mug/ml in pancreaticoduodenal glucagon; in these the associated massive increase in insulin secretion was accompanied by a 35 and 17 mg/100 ml fall in plasma glucose, respectively.
These findings provide further evidence that glucagon secretion can limit the decline in plasma glucose concentration during stimulation of insulin secretion by betacytotropins other than glucose.
Effect of hyperlipacidemic suppression of aminogenic hyperglucagonemia upon plasma glucose response to hyperaminoacidemia. To FIGuRE 5 A The effect of pancreozymin-induced hyperglucagonemia upon the plasma glucose during hyperglycemic suppression of aminogenic hyperglucagonemia.
B. The effect of hyperglycemic inhibition of pancreozymin-induced hyperglucagonemia upon the plasma glucose.
to suppress aminogenic glucagon secretion without hyperglycemia by inducing hyperlipacidemia, recently reported to inhibit glucagon secretion (7) . An intravenous infusion of Lipomul, a triglyceride emulsion, was administered to four dogs at a rate of 1 ml/min and injections of heparin were given intravenously in a dose of 3000 U before and 2000 U at 30 and 90 min after the start of Lipomul infusion. Mean free fatty acid concentration rose from 638 to 3570 ,uEq/ liter with maximum levels ranging from 1800 to 6750 ,uEq/liter. The infusion of the amino acid mixture at a rate of 100 mg/min was begun 60 min after the start of the Lipomul infusion. The results of these experiments are recorded in Fig. 6 . In all but one of these experiments glucagon was assayed with antiserum G-58 which reacts only with pancreatic glucagon.
In only two of the dogs did hyperlipacidemia seem to prevent an aminogenic rise in glucagon above the fasting level. In these two (Fig. 6 A and 6 B,8) , plasma glucose declined 15 and 11 mg/100 ml, respectively. In a third 8Assayed with antiserum G-128, which cross-reacts with extracts of gastrointestinal tissue.
The Role of Aminogenic Glucagon Secretion in Blood Glucose Homeostasis dog, (Fig. 6 C) glucagon rose during the Lipomul infusion to 2.3 m/ug/ml, and 10 min after the amino acid infusion was begun, it rose further to a short-lived peak of 3.8 mug/ml; during this abrupt rise and for 20 min thereafter, glucose changed little, but when the glucagon level returned to the 2.2 mug/ml range, unaccompanied by a concomitant decline in insulin, glucose concentration fell 19 mg/100 ml. The subsequent hyperglycemia occurred after a second rise in glucagon which was unaccompanied by an insulin rise. The other dog (Fig. 6 D) I XU exhibited a rise in glucagon during the amino acid infusion and plasma glucose did not fall below the level at the start of the amino acid infusion. The effect of resection of alpha cell-bearing pancreas upon response to hyperaminoacidemia. Bencosme and Liepa have reported that the alpha cells are sparse in the uncinate process and that its glucagon content is low (8) . Measurement of acid-alcohol extracts of pancreas obtained from four intact dogs immediately after sacrifice revealed a total glucagon content of 0-0.54 tug and an insulin content of 1.0-3.9 U in the uncinate process, as compared to a total pancreatic content of ,ug of glucagon and from 14-33 U of insulin. Thus, in these dogs the uncinate process contained 5-25% of the total insulin but only 1% or less of the total glucagon.
It was hoped, therefore, that the surgical removal of all pancreatic tissue except the uncinate process would yield a dog with a greater deficiency of glucagon than insulin. In such a dog hyperaminoacidemia might stimulate secretion of insulin to a relatively greater degree than glucagon, and the importance of the glucagon response in preventing a fall in glucose could then be evaluated.
Four "uncinate dogs" survived the surgery and endured the postoperative period without morbidity. All but one had a fasting plasma glucose level below 120 mg/ 100 ml at the time of the experiment 3 or more days postoperatively. In these dogs glucagon was assayed in portal vein plasma using antiserum G-58, which is relatively specific for pancreatic glucagon. Two of the four dogs had zero values for glucagon in portal vein plasma and were regarded as glucagon deficient. One such dog (Fig. 7 A) . was given 1 g of amino acid mixture/kg of body weight intraduodenally over a 45 min period and, despite hyperaminoacidemia, portal vein glucagon failed to rise above zero. However, the portal vein insulin rose to 100 ALU/ml and glucose fell 14 mg/100 ml.
The extract of the uncinate process of this dog contained a total of 0.33 ug of glucagon, but insulin was not measured. In the second dog (Fig. 7 B) portal vein glucagon failed to rise above zero during an intravenous infusion of amino acids at a rate of 150 mg/min; the portal vein insulin rose only slightly to 30 uU/ml and plasma glucose did not fall. However, when an infusion of pancreozymin at a rate of 30 U/minute was added, the insulin rose briskly to 376 MAU/ml, the glucagon remained at zero, and glucose fell 16 mg/100 ml. The extract of the uncinate process of this dog contained a total of 0.6 jug of glucagon and 2U of insulin.
In a third dog (Fig. 7 C) both glucagon and insulin rose in parallel during the amino acid infusion and plasma glucose remained constant. When an infusion of pancreozymin was added, a further small rise in insulin took place with little or no rise in glucagon, and glucose fell 14 mg/100 ml. The extract of this dog's pancreatic remnant contained 17.8 jug of glucagon and 3.1 U of insulin. The fourth dog (Fig. 7 D) was overtly diabetic with fasting hyperglycemia and the amino acid infusion caused only a slight rise in insulin; however, a substantial rise in glucagon occurred and this was accompanied by a parallel rise in plasma glucose concentration. When the hyperglucagonemia began to wane after 30 min, the hyperglycemia declined. The administration of pancreozymin was associated with a modest rise in insulin, but, inexplicably, glucagon fell to zero at this point, whereupon a more rapid decline in plasma glucose occurred. The pancreatic remnant of this dog contained 6.2 jug of glucagon and 1.3 U of insulin.
These findings are in keeping with the premise that normoglycemia requires an appropriate secretory relationship between insulin and glucagon. When glucagon secretion is disproportionately low, glucose declines; when insulin is reduced in relation to glucagon, glucose rises. DISCUSSION The foregoing results suggest that the prompt increase in pancreatic glucagon secretion that normally occurs during hyperaminoacidemia in concert with increased insulin secretion serves to limit the decrement in glucose concentration. This conclusion is supported by the demonstration of an inverse relationship between the magnitude of the cataglycemia that occurs during the 1st 60 min of hyperaminoacidemia and the amount of glucagon released during the 1st 20 min, and by the lack of a quantitative relationship between the cataglycemia and the amount of insulin released. Furthermore, when the pancreaticoduodenal vein glucagon concentrations were prevented from rising above the fasting level, either by hyperglycemia, by hyperlipacidemia, or by resection of the glucagon-secreting areas of the pancreas, the magnitude of the glucose fall during hyperaminoacidemia increased. Finally, restoration of hyperglucagonemia, by infusing exogenous glucagon, even at a physiologically suboptimal rate, reduced the cataglycemia during the 1st 30 min of hyperglycemic inhibition of the aminogenic glucagon response; similarly, restoration of hyperglucagonemia by means of pancreozymin-induced "breakthrough" of the hyperglycemic suppression prevented the cataglycemia.
These findings suggest that, were it not for aminogenic hyperglucagonemia, a carbohydrate-free protein meal, as is commonly consumed by carnivores, would result in an important reduction of blood glucose as a consequence of an uncompensated increase in glucose utilization secondary to aminogenic insulin secretion. However, glucagon allows for proper compensation by increasing hepatic glucose production and thus replacing the glucose postulated to enter insulin-sensitive tis-sues in the company of amino acids.9 The fact that glucose infusion so readily inhibits aminogenic hyperglucagonemia at glucose concentrations above 142 mg/100 ml (5) lends additional credence to this concept of glucagon's role.
It may be that the entry of glucose into cells postulated to occur during hyperaminoacidemia is more than merely a passive and inadvertent event without physiologic meaning; Wool and Krahl have found that in the diaphragms of rats fasted 48 hr glucose availability is essential to incorporation of amino acids into protein (19) , the so-called "protein-sparing" effect of glucose.
Although this concept of the role of aminogenic hyperglucagonemia seems well supported in a qualitative sense by the results of this study, these data do not provide quantitative evidence of its physiologic importance. For example, one can argue with some justification that the mean glucose fall of 35 mg/100 ml, which occurred during suppression of aminogenic hyperglucagonemia for 1 hr, hardly constitutes a serious threat, even if it had begun at a normal fasting glucose concentration. Moreover, this decline occurred during hyperglycemia, a state in which other defenses against hypoglycemia might be obtunded, thereby permitting a larger decline in glucose concentration than would have occurred at normal glucose levels. In both the hyperlipacidemic suppression experiments and in the uncinate dog experiments, the initial glucose levels were normal and cataglycemia did not exceed 31 mg/100 ml and averaged considerably less. If the fall in glucose concentration prevented by aminogenic hyperglucagonemia is no larger than this, it is difficult to regard it as an extremely important physiologic protective device. Furthermore, as shown in Table III , the protective effect of exogenous glucagon during hyperglycemic suppression seems to wane after the 1st 30 min of a 60 min glucagon infusion, and by the end of the infusion the plasma glucose has declined as much as in the control experiments, in which no exogenous glucagon had been administered.
However, none of the foregoing arguments necessarily precludes the possibility that the anti-cataglycemic effect of aminogenic hyperglucagonemia is of greater quantitative importance than these data indicate, since each argument can be effectively countered. As for the relatively small glucose decline during suppression of glucagon secretion, it is likely that suppression was incomplete during hyperglycemia; in fact, when hyperaminoacidemia was induced, the mean glucagon concentration rose 0.3 mug/ml above the nadir (Table II) . Furthermore in a realistic physiologic setting hyperaminoaci-glucagon deficiency. It seems entirely possible that the syndrome of idiopathic infantile hypoglycemia, currently attributed to an excessive insulin response to certain amino acids, represents partial or complete glucagon deficiency, a view first proposed by McQuarrie et al. on the basis of the histologic observation of absent alpha cells (25) .
